Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea.
J Korean Med Sci. 2024 Jan 8;39(1):e8. doi: 10.3346/jkms.2024.39.e8.
J Korean Med Sci. 2024.
PMID: 38193327
Free PMC article.
Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
Kim ES, Park SK, Cho DS, Youn JC, Lee HS, Lee HY, Cho HJ, Choi JO, Jeon ES, Lee SE, Kim MS, Kim JJ, Hwang KK, Cho MC, Chae SC, Kang SM, Park JJ, Choi DJ, Yoo BS, Cho JY, Kim KH, Oh BH, Greenberg B, Baek SH.
Kim ES, et al.
Am J Cardiovasc Drugs. 2024 Mar;24(2):313-324. doi: 10.1007/s40256-024-00632-w. Epub 2024 Feb 27.
Am J Cardiovasc Drugs. 2024.
PMID: 38413500
Item in Clipboard
Cite
Cite